Lophius Biosciences further on track to success
Already in September the research company was able to announce a successful round of financing. The investors to date VRD GmbH (Heidelberg), S-Refit AG (Regensburg), Wolf Biotech GmbH (Starnberg), Bayern Kapital (Landshut) and High-Tech Gründerfonds GmbH (Bonn) replenished and thereby facilitated further expansion and marketing of the existing diagnostic kit systems. These are based on the so-called T cells (white blood cells), which serve the body’s immune system. These allow the early diagnosis of infectious diseases and autoimmune disease.
As a result of growth of the company, meanwhile the management has been further expanded to 25 employees. Since October Bernd Merkl has been on board and known by many at the BioPark from his successful time at the company Geneart. There he was amongst other roles on the board of directors for sales and marketing and after the acquisitions by Life Technologies and Thermo Fisher Scientific most recently Location Manager of the Center of Excellence for Synthetic Biology in Regensburg for the global market. He can also now use this experience for Diagnostic Kits at Lophius.
For further information see: